Clinical Trial

EMBRACE Study: Enduring Migraine Benefit From Responsive Artery Coil Embolization

Study acronym: EMBRACE
Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
This single-site, open-label pilot study evaluates the safety, feasibility, and potential durability of the TEMMA procedure (Targeted Embolization for Migraine Management), an endovascular treatment strategy targeting meningeal arterial contributors to migraine. Adults aged 18-60 with refractory migraine despite prior preventive therapies are eligible. The study assesses migraine outcomes over 12 months using patient-reported headache frequency, pain intensity, acute medication use, migraine-related disability (MIDAS), and quality-of-life measures (MSQ v2.1).
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-12-30; most recent amendment 2026-02-02.
Trial Details
NCT Number NCT07313800
Lead Sponsor Cortex Neurovascular
Conditions Migraine Disorders, Refractory Migraine, Chronic Migraine
Enrollment 25 participants
Start Date 2026-03-01
Primary Completion 2027-03-01 (estimated)
Study Completion 2028-03-01 (estimated)
Updated on ClinicalTrials.gov 2026-02-04